JP7739051B2 - シクロブチルジヒドロキノリンスルホンアミド化合物 - Google Patents

シクロブチルジヒドロキノリンスルホンアミド化合物

Info

Publication number
JP7739051B2
JP7739051B2 JP2021090960A JP2021090960A JP7739051B2 JP 7739051 B2 JP7739051 B2 JP 7739051B2 JP 2021090960 A JP2021090960 A JP 2021090960A JP 2021090960 A JP2021090960 A JP 2021090960A JP 7739051 B2 JP7739051 B2 JP 7739051B2
Authority
JP
Japan
Prior art keywords
dihydroquinoline
oxo
sulfonamide
fluoro
cyclobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021090960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021195368A (ja
Inventor
ベンジャミン・シー・ミルグラム
アイザック・イー・マークス
ハオシュアン・ワン
アラン・エイチ・チャーニー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2021195368A publication Critical patent/JP2021195368A/ja
Priority to JP2025145171A priority Critical patent/JP2025179137A/ja
Application granted granted Critical
Publication of JP7739051B2 publication Critical patent/JP7739051B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2021090960A 2020-06-10 2021-05-31 シクロブチルジヒドロキノリンスルホンアミド化合物 Active JP7739051B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025145171A JP2025179137A (ja) 2020-06-10 2025-09-02 シクロブチルジヒドロキノリンスルホンアミド化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063037001P 2020-06-10 2020-06-10
US63/037,001 2020-06-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025145171A Division JP2025179137A (ja) 2020-06-10 2025-09-02 シクロブチルジヒドロキノリンスルホンアミド化合物

Publications (2)

Publication Number Publication Date
JP2021195368A JP2021195368A (ja) 2021-12-27
JP7739051B2 true JP7739051B2 (ja) 2025-09-16

Family

ID=76797115

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021090960A Active JP7739051B2 (ja) 2020-06-10 2021-05-31 シクロブチルジヒドロキノリンスルホンアミド化合物
JP2025145171A Pending JP2025179137A (ja) 2020-06-10 2025-09-02 シクロブチルジヒドロキノリンスルホンアミド化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025145171A Pending JP2025179137A (ja) 2020-06-10 2025-09-02 シクロブチルジヒドロキノリンスルホンアミド化合物

Country Status (31)

Country Link
US (3) US12240839B2 (https=)
EP (2) EP4165024B1 (https=)
JP (2) JP7739051B2 (https=)
KR (1) KR20230022996A (https=)
CN (2) CN119735588A (https=)
AR (1) AR122592A1 (https=)
AU (1) AU2021288696A1 (https=)
BR (1) BR112022025201A2 (https=)
CA (1) CA3183889A1 (https=)
CL (1) CL2022003499A1 (https=)
CO (1) CO2022017903A2 (https=)
CR (1) CR20220631A (https=)
DK (1) DK4165024T3 (https=)
ES (1) ES3037072T3 (https=)
FI (1) FI4165024T3 (https=)
HR (1) HRP20251229T1 (https=)
HU (1) HUE072945T2 (https=)
IL (2) IL326793A (https=)
JO (1) JOP20220334A1 (https=)
LT (1) LT4165024T (https=)
MA (1) MA59968B1 (https=)
MX (2) MX2022015856A (https=)
PE (1) PE20230860A1 (https=)
PL (1) PL4165024T3 (https=)
PT (1) PT4165024T (https=)
RS (1) RS67268B1 (https=)
SI (1) SI4165024T1 (https=)
SM (1) SMT202500328T1 (https=)
TW (1) TWI899251B (https=)
UY (1) UY39263A (https=)
WO (1) WO2021252820A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
JP2021195367A (ja) * 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
HRP20260068T1 (hr) 2021-06-04 2026-02-27 Vertex Pharmaceuticals Incorporated Čvrsti farmaceutski oblici i režimi doziranja koji obuhvaćaju (2r,3s,4s,5r)-4-[[3-(3,4-difluor-2-metoksifenil)-4,5-dimetil-5-(trifluormetil)tetrahidrofuran-2-karbonil]amino]piridin-2-karboksamid
AU2022283934A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CA3221938A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
US20240400544A1 (en) 2021-06-04 2024-12-05 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
KR20240046891A (ko) * 2021-08-12 2024-04-11 티와이케이 메디슨즈, 인코포레이티드 다환 화합물 및 그의 용도
CA3257285A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CA3256248A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521749A (ja) 2013-06-12 2016-07-25 アムジエン・インコーポレーテツド ナトリウムチャネル阻害剤としての二環式スルホンアミド化合物
WO2016124139A1 (zh) 2015-02-04 2016-08-11 上海海雁医药科技有限公司 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途
JP2019504016A (ja) 2015-12-18 2019-02-14 アムジエン・インコーポレーテツド アルキルジヒドロキノリンスルホンアミド化合物
JP2021195367A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4412994A (en) 1980-04-24 1983-11-01 Interx Research Corporation Mannich-base hydroxamic acid prodrugs, compositions and use
US5707985A (en) 1995-06-07 1998-01-13 Tanabe Seiyaku Co. Ltd. Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators
PA8444901A1 (es) 1997-01-28 2000-05-24 Hoffmann La Roche Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios
CN1315836C (zh) 2002-04-26 2007-05-16 奥索-麦克尼尔药品公司 用作雄激素受体调节剂的2－(喹诺酮基)－稠合杂环
BRPI0406778A (pt) 2003-01-17 2006-01-17 Warner Lambert Co Antagonistas de receptores de androgênio
US7009052B2 (en) 2003-03-20 2006-03-07 Warner Lambert Company Llc Sulfonamide derivatives
WO2006117762A2 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Antimicrobial agents
MX2007014180A (es) 2005-05-10 2008-01-14 Vertex Pharma Derivados biciclicos como moduladores de canales de iones.
CA2608599A1 (en) 2005-05-16 2006-11-23 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
CN102471235A (zh) 2009-07-11 2012-05-23 拜耳医药股份有限公司 利用环烷基的放射性标记方法
CN102030780B (zh) * 2010-10-26 2014-01-29 浙江大学 一种手性螺环磷酸和制备方法及其应用
MX2014001851A (es) 2011-08-17 2014-10-24 Amgen Inc Inhibidores del canal de heteroarilo sodio.
US9012443B2 (en) 2011-12-07 2015-04-21 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
WO2013134518A1 (en) 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
EA032928B1 (ru) 2015-03-02 2019-08-30 Эмджен Инк. Бициклические кетосульфонамидные соединения
MX378012B (es) * 2015-12-18 2025-03-10 Amgen Inc Compuestos de alquinil dihidroquinolina sulfonamida.
CN109563045B (zh) * 2016-03-21 2022-08-23 斯克里普斯研究学院 Pd(II)-催化的对映选择性β-亚甲基C(sp3)-H键活化
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
KR20240046891A (ko) 2021-08-12 2024-04-11 티와이케이 메디슨즈, 인코포레이티드 다환 화합물 및 그의 용도
MX2024002176A (es) 2021-08-19 2024-03-12 Amgen Inc Preparacion estereoselectiva de ciclobutano trans halo.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521749A (ja) 2013-06-12 2016-07-25 アムジエン・インコーポレーテツド ナトリウムチャネル阻害剤としての二環式スルホンアミド化合物
WO2016124139A1 (zh) 2015-02-04 2016-08-11 上海海雁医药科技有限公司 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途
JP2019504016A (ja) 2015-12-18 2019-02-14 アムジエン・インコーポレーテツド アルキルジヒドロキノリンスルホンアミド化合物
JP2021195367A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物

Also Published As

Publication number Publication date
CL2022003499A1 (es) 2023-08-04
EP4653050A3 (en) 2026-04-15
MA59968B1 (fr) 2025-10-31
KR20230022996A (ko) 2023-02-16
BR112022025201A2 (pt) 2023-02-28
TW202214586A (zh) 2022-04-16
SMT202500328T1 (it) 2025-11-10
CN115697971B (zh) 2025-01-28
RS67268B1 (sr) 2025-10-31
IL326793A (en) 2026-04-01
AU2021288696A1 (en) 2022-12-15
US20210387978A1 (en) 2021-12-16
PT4165024T (pt) 2025-10-23
PL4165024T3 (pl) 2025-12-08
MX2022015856A (es) 2023-01-24
CN115697971A (zh) 2023-02-03
US20220306604A1 (en) 2022-09-29
DK4165024T3 (da) 2025-09-08
CR20220631A (es) 2023-01-23
JOP20220334A1 (ar) 2023-01-30
IL298325B1 (en) 2026-04-01
HUE072945T2 (hu) 2025-12-28
PE20230860A1 (es) 2023-05-30
EP4165024A1 (en) 2023-04-19
JP2025179137A (ja) 2025-12-09
LT4165024T (lt) 2025-11-10
SI4165024T1 (sl) 2025-12-31
US12240839B2 (en) 2025-03-04
IL298325A (en) 2023-01-01
CN119735588A (zh) 2025-04-01
CA3183889A1 (en) 2021-12-16
JP2021195368A (ja) 2021-12-27
CO2022017903A2 (es) 2022-12-20
EP4653050A2 (en) 2025-11-26
HRP20251229T1 (hr) 2025-12-19
AR122592A1 (es) 2022-09-21
ES3037072T3 (en) 2025-09-26
TWI899251B (zh) 2025-10-01
FI4165024T3 (fi) 2025-08-29
EP4165024B1 (en) 2025-07-16
US20250171425A1 (en) 2025-05-29
MX2025010506A (es) 2025-10-01
WO2021252820A1 (en) 2021-12-16
UY39263A (es) 2021-11-30

Similar Documents

Publication Publication Date Title
JP7739051B2 (ja) シクロブチルジヒドロキノリンスルホンアミド化合物
EP4164748B1 (en) Cyclopropyl dihydroquinoline sulfonamide compounds
EP4165032B1 (en) Heteroalkyl dihydroquinoline sulfonamide compounds
CA2978569C (en) Bicyclic ketone sulfonamide compounds
HK1248687A1 (en) Bicyclic ketone sulfonamide compounds
EP3390393A1 (en) Alkynyl dihydroquinoline sulfonamide compounds
EA050562B1 (ru) Циклобутилдигидрохинолинсульфонамидные соединения
HK40083542A (en) Cyclobutyl dihydroquinoline sulfonamide compounds
HK40083542B (en) Cyclobutyl dihydroquinoline sulfonamide compounds

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240507

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250708

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250805

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250903

R150 Certificate of patent or registration of utility model

Ref document number: 7739051

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150